Takeda Pharmaceutical
304 hedge funds and large institutions have $1.6B invested in Takeda Pharmaceutical in 2021 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 93 increasing their positions, 103 reducing their positions, and 41 closing their positions.
105% more call options, than puts
Call options by funds: $58.8M | Put options by funds: $28.6M
0.82% less ownership
Funds ownership: 6.84% → 6.02% (-0.82%)
10% less repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 103
4% less funds holding
Funds holding: 316 → 304 (-12)
19% less capital invested
Capital invested by funds: $1.97B → $1.6B (-$368M)
29% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 41
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.4M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$12.9M |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$11.2M |
| 4 |
Citigroup
New York
|
+$8.41M |
| 5 |
Barclays
London,
United Kingdom
|
+$7.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Glenview Capital Management
New York
|
-$119M |
| 2 |
PC
Paulson & Co
New York
|
-$86.3M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$54.9M |
| 4 |
GC
GMT Capital
Atlanta,
Georgia
|
-$21.3M |
| 5 |
Renaissance Technologies
New York
|
-$19.4M |
TAK Hedge Fund Activity: Q2 2021 in Review
304 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q2 2021, worth a combined $1.6B — down 19% from $1.97B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of TAK and 29 opened new positions — a net loss of 12 holders — while 103 trimmed existing stakes and 93 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $23.4M. The largest seller was Glenview Capital Management, cutting an estimated $119M.
- 304 institutional investors held Takeda Pharmaceutical (TAK) as of Q2 2021, down from 316 in Q1 2021.
- Funds reported $1.6B of Takeda Pharmaceutical stock for Q2 2021, down 19% quarter-over-quarter.
- 29 funds opened new Takeda Pharmaceutical positions in Q2 2021 and 41 closed out, a net change of -12 holders.
- The largest Takeda Pharmaceutical buyer in Q2 2021 was Point72 Asset Management, an estimated $23.4M added.
- The largest Takeda Pharmaceutical seller in Q2 2021 was Glenview Capital Management, an estimated $119M sold.
Based on aggregated 13F filings for Q2 2021.